How many clinical trials are recruiting for cannabis use disorder?

32 drug-interventional cannabis use disorder trials are currently recruiting participants, out of 109 registered interventional trials.

Substance Use Disorders

Cannabis use disorder drug pipeline

ICD-11 6C41
MeSH D002189

1 compound from 1 company is in active clinical development for cannabis use disorder.

1Compound

1Company

0Phase 3+

33Trials recruiting

Phase 2 1

Mechanisms: Small molecule (1)

Pipeline data compiled July 2026 · every fact sourced.

Upcoming readouts & recent results

2025-03-26ReportedAEF0117 (lixosicone)Full resultsmissedNCT05322941
Final SICA2 analysis: primary endpoint confirmed not met; 1 mg reduced days of cannabis use (-16% vs placebo, P=0.077) with a positive high-motivation subgroup (P=0.038). ↗
2024-09-03ReportedAEF0117 (lixosicone)Topline datamissedNCT05322941
Phase 2b SICA2 missed its primary responder endpoint (cannabis use <=1 day/week) and key secondary abstinence endpoints. ↗

See the full catalyst calendar →

Compounds in development (1)

Compound	Company	Phase	Status	Mechanism
AEF0117 (lixosicone)	Aelis Farma S.A.	Phase 2	Active	CB1 NAM

Trials recruiting now (32)

32 drug-interventional cannabis use disorder trials recruiting now, of 109 registered interventional trials. Browse all on ClinicalTrials.gov →

Phase 4Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Metformin
Nova Scotia Health Authorityn=24Canada · 2 sitesStarted Mar 2025NCT07001878
Phase 4Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)
Suvorexant
Massachusetts General Hospitaln=20United States · 1 siteStarted Mar 2025NCT06584942
Phase 3Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
Nabilone, Placebo
PleoPharma, Inc.n=420United States · 10 sitesStarted Jun 2026NCT07644052
Phase 3Cannabis-Tobacco Co-Use Treatment Study
Varenicline
Medical University of South Carolinan=200United States · 1 siteStarted May 2025NCT06883162
Phase 2Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
Tirzepatide, Placebo
National Institute on Drug Abuse (NIDA)n=100Started Nov 2026NCT07468552
Phase 2Tirzepatide for the Treatment of Cannabis Use Disorder
Tirzepatide, Placebo
Brigham and Women's Hospitaln=6Started Jul 2026NCT07265752
Phase 2Acute Effects of Cannabis on Cognition and Affect
THC 20mg, Placebo
Washington State Universityn=90United States · 1 siteStarted Jul 2026NCT07296874
Phase 2Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
semaglutide, Placebo
Anders Fink-Jensen, MD, DMScin=100Denmark · 1 siteStarted Apr 2026NCT07523633
Phase 2Sex Differences in Neurobehavioral Response to THC
Dronabinol, Placebo
Medical University of South Carolinan=40United States · 1 siteStarted Apr 2026NCT07225777
Phase 2Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
Cannabis, Nicotine
University of California, San Franciscon=48United States · 1 siteStarted Jul 2025NCT05999383
Phase 2Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Psilocybin combined with Psychotherapy
McMaster Universityn=16Canada · 1 siteStarted Mar 2025NCT06225232
Phase 2A Study of Cannabidiol in Young Adult Cannabis Users
Broad Spectrum Cannabidiol (bsCBD) 400 mg, Placebo
University of Colorado, Denvern=200United States · 1 siteStarted Dec 2024NCT06569394

Showing the 12 most advanced of 32 recruiting drug trials · see all on ClinicalTrials.gov →

Frequently asked

How many drugs are in development for cannabis use disorder?: 1 compound from 1 company is in active clinical development for cannabis use disorder.
How many clinical trials are recruiting for cannabis use disorder?: 32 drug-interventional cannabis use disorder trials are currently recruiting participants, out of 109 registered interventional trials.